Literature DB >> 30543365

Cytoreductive Nephrectomy in Metastatic Renal Cell Cancer: Not All That It's Cut Out to Be.

Primo N Lara1,2, Christopher P Evans1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30543365     DOI： 10.1001/jamaoncol.2018.5503

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  11 in total

1.  Stereotactic body radiation therapy for oligometastatic renal cell carcinoma: improving outcomes in an otherwise radioresistant malignancy.

Authors:  Thomas H Beckham; Brandon S Imber; Charles B Simone
Journal:  Ann Transl Med       Date:  2019-07

Review 2.  Use of Circular RNAs in Diagnosis, Prognosis and Therapeutics of Renal Cell Carcinoma.

Authors:  Rebeca Osca-Verdegal; Jesús Beltrán-García; José Luis Górriz; José María Martínez Jabaloyas; Federico V Pallardó; José Luis García-Giménez
Journal:  Front Cell Dev Biol       Date:  2022-06-22

3.  Survival Impact of Nephroureterectomy for De Novo Stage IV Nonmetastatic and Metastatic Upper Tract Urothelial Carcinoma.

Authors:  Wei-Yu Lin; Meng-Hung Lin; Yao-Hsu Yang; Wen-Cheng Chen; Cih-En Huang; Miao-Fen Chen; Chun-Te Wu
Journal:  Front Surg       Date:  2022-05-26

Review 4.  Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.

Authors:  Bulent Cetin; Chiara A Wabl; Ozge Gumusay
Journal:  Curr Treat Options Oncol       Date:  2022-03-22

5.  Noncoding-RNA mediated high expression of zinc finger protein 268 suppresses clear cell renal cell carcinoma progression by promoting apoptosis and regulating immune cell infiltration.

Authors:  Keyi Wang; Yongzhe Gu; Jinliang Ni; Houliang Zhang; Yidi Wang; Yifan Zhang; Xianchao Sun; Tianyuan Xu; Weipu Mao; Bo Peng
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

6.  circAMOTL1L Suppresses Renal Cell Carcinoma Growth by Modulating the miR-92a-2-5p/KLLN Pathway.

Authors:  Ling Gao; Xian Shao; Qingqing Yue; Weifei Wu; Xuejuan Yang; Xiaolei He; Limin Li; Fujun Hou; Ruonan Zhang
Journal:  Oxid Med Cell Longev       Date:  2021-10-04       Impact factor: 6.543

Review 7.  CircRNAs as Novel Biomarkers and Therapeutic Targets in Renal Cell Carcinoma.

Authors:  Yuxia Zhou; Cheng Li; Zhenping Wang; Shuangfeng Tan; Yiqi Liu; Hu Zhang; Xuefeng Li
Journal:  Front Mol Biosci       Date:  2022-02-11

8.  Construction and Verification of a Combined Hypoxia and Immune Index for Clear Cell Renal Cell Carcinoma.

Authors:  Bin Wang; Lixiao Liu; Jinting Wu; Xiaolu Mao; Zhen Fang; Yingyu Chen; Wenfeng Li
Journal:  Front Genet       Date:  2022-02-09       Impact factor: 4.599

9.  circPRRC2A promotes angiogenesis and metastasis through epithelial-mesenchymal transition and upregulates TRPM3 in renal cell carcinoma.

Authors:  Wei Li; Feng-Qiang Yang; Chen-Min Sun; Jian-Hua Huang; Hai-Min Zhang; Xue Li; Guang-Chun Wang; Ning Zhang; Jian-Ping Che; Wen-Tao Zhang; Yang Yan; Xu-Dong Yao; Bo Peng; Jun-Hua Zheng; Min Liu
Journal:  Theranostics       Date:  2020-03-15       Impact factor: 11.556

Review 10.  Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy.

Authors:  Ying Wang; Yunjing Zhang; Ping Wang; Xianghui Fu; Weiqiang Lin
Journal:  Mol Cancer       Date:  2020-10-14       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.